NCTN Lead Academic Participating Sites Application

NCTN牵头学术参赛站点申请

• 批准号: 9056543
• 负责人: LISA A CAREY
• 金额: $ 47.43万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-07 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9056543
• 关键词: American College of Surgeons Oncology Group; Cancer Patient; Cancer and Leukemia Group B; Caring; Clinic; Clinical; Clinical Research; Clinical Trials; Communities; Development; Discipline; Disease; Faculty; Funding; Future; Genomics; Gynecologic Oncology Group; Health; Health Services Research; Investments; Knowledge; Lead; Leadership; Learning; Malignant Neoplasms; Medical Oncology; Oncologist; Outcome; Patients; Policies; Radiation Oncology; Research; Research Activity; Research Infrastructure; Resources; Site; Surgical Oncology; Translational Research; base; cancer therapy; care delivery; cost effectiveness; improved; improved outcome; multidisciplinary; next generation sequencing; tumor progression

DESCRIPTION (provided by applicant): As a National Clinic Trials Network Lead Academic Participating Site, we hope to accomplish the following: 1. To provide scientific leadership and intellectual input in the creation of thoughtful, feasible trials to improve the health of cancer patients. We will accomplish this aim through the ongoing participation in clinical trials that spn the spectrum of disease-specific and radiation and surgical oncology; by applying the UNC culture of multidisciplinary care to make NCTN trials stronger and more modern; by leveraging the commitment of junior faculty, who will be the leaders of tomorrow; and by applying health services research in the development of clinical trials, including factors important to clinical outcomes, such as cost effectiveness, delivery of care, and policy. 2. To continue to be strong supporters of Network trials, through our rapidly growing clinical enterprise and robust accrual. We will support this aim by building on our historically strong accrual to CALGB, GOG, and ACOSOG trials and our well-funded and organized infrastructure, and through active participation across the NCTN. 3. To provide opportunities for excellent translational science embedded in NCTN clinical trials. UNC has a long commitment to translational science and has served as reference lab across multiple trials, with substantial (more than $3 million) investment in Next Generation sequencing and genomics; we are well suited to serve as a translational research collaborator for clinical trials in the future.

描述（由申请人提供）：作为国家临床试验网络领导学术参与网站，我们希望实现以下目标：1。提供科学的领导和智力投入，创造深思熟虑的，可行的试验，以改善癌症患者的健康。我们将通过持续参与spn疾病特异性和放射和外科肿瘤学的临床试验来实现这一目标;通过应用多学科护理的文化，使NCTN试验更强大，更现代化;通过利用初级教师的承诺，他们将成为明天的领导者;以及通过将卫生服务研究应用于临床试验的开发，包括对临床结果很重要的因素，如成本效益、护理提供和政策。2.通过我们快速增长的临床业务和强劲的收益，继续成为网络试验的坚定支持者。我们将通过建立我们对CALGB，GOG和ACOSOG试验的历史性强的应计费用以及我们资金充足和组织良好的基础设施，并通过积极参与整个NCTN来支持这一目标。3.为NCTN临床试验中嵌入的优秀转化科学提供机会。 我们长期致力于转化科学，并在多项试验中担任参考实验室，在下一代测序和基因组学方面有大量投资（超过300万美元）;我们非常适合在未来担任临床试验的转化研究合作者。